OR WAIT null SECS
April 22, 2024
Technology designed to effectively address blood clots by combining capabilities of larger devices with smaller catheters.
April 19, 2024
Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.
April 18, 2024
Data displayed rapid and sustained B-cell depletion, with 97.2% of study patients with relapsing and primary progressive multiple sclerosis experiencing no relapses.
April 17, 2024
Data from the Phase III APPLAUSE-IgAN study showed a 38.3% reduction in proteinuria in patients treated with Fabhalta for IgA nephropathy compared to placebo.
April 15, 2024
Phase IIa clinical trial of SPG60 for Fragile X syndrome offers hope for disease with no current FDA-approved treatment options.
April 11, 2024
A cohort study digs into whether there is an improvement in overall survival or quality of life within five years of the FDA granting accelerated approval to oncology drugs.
April 01, 2024
Cross-sectional study explores the impact of this monumental Supreme Court ruling.
March 29, 2024
Exploring how current and future legislation may impact the role of pharmacy benefit managers (PBMs).
March 27, 2024
A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications.
March 19, 2024
Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.